Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà

Âåðíóòüñÿ   Äèñêóññèîííûé Êëóá Ðóññêîãî Ìåäèöèíñêîãî Ñåðâåðà > Äèñêóññèîííûå ôîðóìû > Ðàçíîå

Ðàçíîå Ëþáûå ñîîáùåíèÿ íà ìåäèöèíñêèå òåìû, ïî êîòîðûì íåò îòäåëüíûõ ôîðóìîâ. Ôîðóì: ×àñòíàÿ ïðàêòèêà.

Îòâåò
 
Îïöèè òåìû Ïîèñê â ýòîé òåìå Îïöèè ïðîñìîòðà
  #211  
Ñòàðûé 26.02.2010, 21:58
Àâàòàð äëÿ Anna_Shvedova
Anna_Shvedova Anna_Shvedova âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 24.02.2006
Ãîðîä: Âîðîíåæ
Ñîîáùåíèé: 16,025
Ïîáëàãîäàðèëè 4,808 ðàç(à) çà 4,645 ñîîáùåíèé
Anna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñïàñèáî, êîëëåãè. Âîò òàê âñåãäà - ñìûñë ÿñåí, à "êàê ýòî áóäåò ïî-ðóññêè".. "àíàëèçèðóåòñÿ íà ïðîòÿæåíèè âñåé æèçíè" - ýòî ñêîðåå ê ñìûñëó, ÷åì "ïî-ðóññêè", ÈÌÕÎ Ðå÷ü èäåò î ìîäåëè ðàñ÷åòà ôàðìàêîýêîíîìè÷åñêîé ýôôåêòèâíîñòè ëå÷åíèÿ èñõîäÿ èç îæèäàåìîé ïðîäîëæèòåëüíîñòè æèçíè.
__________________
Àííà, âðà÷-ýíäîêðèíîëîã
Âîðîíåæ, êëèíèêà Íåïëàöåáî
Îòâåòèòü ñ öèòèðîâàíèåì
  #212  
Ñòàðûé 26.02.2010, 22:03
Vlad34 Vlad34 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 31.10.2008
Ãîðîä: Âîðîíåæ
Ñîîáùåíèé: 7,362
Ïîáëàãîäàðèëè 518 ðàç(à) çà 480 ñîîáùåíèé
Vlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ëó÷øå áû êîíå÷íî [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Åùå ëó÷øå êîíå÷íî áû ïîëíûé.
Îòâåòèòü ñ öèòèðîâàíèåì
  #213  
Ñòàðûé 26.02.2010, 22:09
Àâàòàð äëÿ Anna_Shvedova
Anna_Shvedova Anna_Shvedova âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 24.02.2006
Ãîðîä: Âîðîíåæ
Ñîîáùåíèé: 16,025
Ïîáëàãîäàðèëè 4,808 ðàç(à) çà 4,645 ñîîáùåíèé
Anna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåAnna_Shvedova ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äà, ýòî îíî, Øåðëîê. ß, ïðàâäà, áðàëà èç ìåäñêåéïà òåêñò, ñëîâà íåìíîãî äðóãèå, íî ñìûñë òîò æå.
__________________
Àííà, âðà÷-ýíäîêðèíîëîã
Âîðîíåæ, êëèíèêà Íåïëàöåáî
Îòâåòèòü ñ öèòèðîâàíèåì
  #214  
Ñòàðûé 26.02.2010, 22:21
OlgaVr OlgaVr âíå ôîðóìà ÂÐÀ×
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.08.2008
Ãîðîä: Switzerland
Ñîîáùåíèé: 77
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 8 ðàç(à) çà 8 ñîîáùåíèé
OlgaVr ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
lifetime analytic horizon

Ànalytic horizon the period of time after an intervention ends, during wich cost and outcomes accrue and are measured.

Áûâàåò êðàòêîñðî÷íûé, êîãäà âàæíûå ðåçóëüòàòû ìîãóò áûòü èçìåðåíû â êîðîòêîå âðåìÿ. Ïîýòîìó ïåðåâåëà áû "ïðîäîëæèòåëüíîñòü (âðåìÿ ñóùåñòâîâàíèÿ) àíàëèòè÷åñêîãî ãîðèçîíòà"
Îòâåòèòü ñ öèòèðîâàíèåì
  #215  
Ñòàðûé 26.02.2010, 22:53
Vlad34 Vlad34 âíå ôîðóìà ÂÐÀ×
Âðà÷-ó÷àñòíèê ôîðóìà
      
 
Ðåãèñòðàöèÿ: 31.10.2008
Ãîðîä: Âîðîíåæ
Ñîîáùåíèé: 7,362
Ïîáëàãîäàðèëè 518 ðàç(à) çà 480 ñîîáùåíèé
Vlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåVlad34 ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
"Àíàëèòè÷åñêèé ïåðèîä" ÷òî-ëè, "àíàëèòè÷åñêèé ïåðèîä â òå÷åíèè/íà ïðîòÿæåíèè âñåé æèçíè". Âîò òóò åùå ïðî ýòî [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Öèòàòà:
In contrast, the
analytic horizon (or time horizon) refers to the entire period during which the
costs and benefits are measured. If all the important results of an intervention
can be measured in the short term, then the analytic horizon will be
short. For most prevention programs, the analytic horizon should be sufficient
to assess all of the benefits of the program. However, it is important to
note that health effects may be realized long after the intervention has concluded
and may span a person’s lifetime. For example, consider a tobacco
cessation program. With such a program, the time frame during which the
intervention is delivered may be relatively short, possibly one year or less.
However, the analytic horizon would include the lifetime of the (former)
smoker to account for the period over which the benefits of reducing tobaccorelated
illnesses (e.g., cancer or heart disease) are realized. The value of the
benefits that accrue during the analytic horizon must be included in the economic
analysis.
Îòâåòèòü ñ öèòèðîâàíèåì
  #216  
Ñòàðûé 13.03.2010, 19:50
aberzoy aberzoy âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 03.02.2003
Ãîðîä: Îäåññà
Ñîîáùåíèé: 5,681
Ïîáëàãîäàðèëè 1,128 ðàç(à) çà 1,080 ñîîáùåíèé
aberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ïðîñòî äëÿ îòçûâ÷èâûõ ïîìîùíèêîâ.

"For some strange reason the general opinion among doctors is that if one writes a book he must have superior knowledge of the subject. Since no one troubles to read the book the delusion is not discovered."
(--Arthur E. Hertzler, 1870-1946)


“We know that many practicing physicians are not using well proven interventions or implementing well-publicized national guidelines. The legal definition of standard of care protects these physicians and encourage them to change slowly, if at all.”
(--Daniel Merenstein)

“In America…when a patient asks you to take care of her, you will do everything within your power to cure her disease. Failing that, you will do everything within your power to prolong her life. And failing that, you will do everything within your power to relieve her suffering. The problem with that ethic is the world “everything”. Everything may be unnecessary.
(--Alan Robert Spievack)
Îòâåòèòü ñ öèòèðîâàíèåì
  #217  
Ñòàðûé 18.03.2010, 23:08
aberzoy aberzoy âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 03.02.2003
Ãîðîä: Îäåññà
Ñîîáùåíèé: 5,681
Ïîáëàãîäàðèëè 1,128 ðàç(à) çà 1,080 ñîîáùåíèé
aberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Äîáðûé âå÷åð!

Ïðîäîëæèì? :-)

Several large randomized trials that have compared commonly prescribed platinum doublets did not support any specific regimen as the evidenced-based practice standard for NSCLC

Ñîáñòâåííî, èíòåðåñóåò "êðàñèâû" ïåðåâîä íà ðóññêèé âûäåëåííîãî öâåòîì...

lack overlapping toxic effects - íåñîâïàäåíèå ïðîôèëåé òîêñè÷íîñòè?
Îòâåòèòü ñ öèòèðîâàíèåì
  #218  
Ñòàðûé 19.03.2010, 00:37
OlgaVr OlgaVr âíå ôîðóìà ÂÐÀ×
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.08.2008
Ãîðîä: Switzerland
Ñîîáùåíèé: 77
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 8 ðàç(à) çà 8 ñîîáùåíèé
OlgaVr ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
as the evidenced-based practice standard - êàê äîêàçàííûé ñòàíäàðò ïðèìåíåíèÿ äëÿ ëå÷åíèÿ NSCLC

lack overlapping toxic effects - îòñóòñòâèå ñîâìåùåííûõ òîêñè÷åñêèõ ýôôåêòîâ

doublets - ïàðíàÿ/äóáëåò õèìèîòåðàïèÿ.
Îòâåòèòü ñ öèòèðîâàíèåì
  #219  
Ñòàðûé 19.03.2010, 01:30
Àâàòàð äëÿ Iluhin
Iluhin Iluhin âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 24.03.2006
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 5,879
Ñêàçàë(à) ñïàñèáî: 9
Ïîáëàãîäàðèëè 1,327 ðàç(à) çà 1,195 ñîîáùåíèé
Iluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåIluhin ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
lack overlapping toxic effects - ìíå êàæåòñÿ, "ñîâìåùåííûõ òîêñè÷åñêèõ ýôôåêòîâ" êàê-òî íå î÷åíü. Íå çâó÷èò îáîðîò "ñîâìåùåííûå òîêñè÷åñêèå ýôôåêòû". Òî åñòü overlapping êàê "ñîâìåùåíèå", "íàëîæåíèå", "ïåðåõëåñò", ìíå êàæåòñÿ, íàäî ïåðåâîäèòü êàê "îòñóòñòâèå íàëîæåíèÿ (ñóììèðîâàíèÿ) òîêñè÷åñêèõ ýôôåêòîâ".
__________________
Èëþõèí Åâãåíèé Àðêàäüåâè÷
Îòâåòèòü ñ öèòèðîâàíèåì
  #220  
Ñòàðûé 19.03.2010, 02:02
aberzoy aberzoy âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 03.02.2003
Ãîðîä: Îäåññà
Ñîîáùåíèé: 5,681
Ïîáëàãîäàðèëè 1,128 ðàç(à) çà 1,080 ñîîáùåíèé
aberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñïàñèáî çà ïðåäëîæåíèÿ!

Åù¸ âîò, ñêîðåå â òåðìèíîëîãèþ íàäî áóäåò çàòåì -
TTP curves were constructed using the Kaplan–Meier product limit method


À çäåñü ïðîñòî ïîíðàâèëîñü îáúåäèíåíèå â îäíîì ïðåäëîæåíèè ïàðàìåòðîâ ñðàâíåíèÿ:

Within the ITT population, 17.1% had brain metastases and 12.2%
were African-American.

Îòâåòèòü ñ öèòèðîâàíèåì
  #221  
Ñòàðûé 19.03.2010, 11:00
OlgaVr OlgaVr âíå ôîðóìà ÂÐÀ×
Íà÷èíàþùèé ó÷àñòíèê
 
Ðåãèñòðàöèÿ: 20.08.2008
Ãîðîä: Switzerland
Ñîîáùåíèé: 77
Ñêàçàë(à) ñïàñèáî: 2
Ïîáëàãîäàðèëè 8 ðàç(à) çà 8 ñîîáùåíèé
OlgaVr ýòîò ó÷àñòíèê èìååò õîðîøóþ ðåïóòàöèþ íà ôîðóìå
the Kaplan–Meier product limit method - ìåòîä Êàïëàí-Ìàéåðà èëè ìåòîä ðàñ÷åòà ïðîèçâåäåíèÿ ïðåäåëîâ/èíòåðâàëüíûõ ïîêàçàòåëåé

Kaplan-Meier Product-Limit Estimator
Rather than classifying the observed survival times into a life table, we can estimate the survival function directly from the continuous survival or failure times. Intuitively, imagine that we create a life table so that each time interval contains exactly one case. Multiplying out the survival probabilities across the "intervals" (i.e., for each single observation) we would get for the survival function: êàðòèíêó ñ ôîðìóëîé íå ïîëó÷èëîñü âñòàâèòü, ïîýòîìó ïðîäîëæåíèå çäåñü [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]

Íà ðóññêîì ñòàòüÿ î ìåòîäå Êàïëàí-Ìàéåðà [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
Îòâåòèòü ñ öèòèðîâàíèåì
  #222  
Ñòàðûé 20.03.2010, 23:09
aberzoy aberzoy âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 03.02.2003
Ãîðîä: Îäåññà
Ñîîáùåíèé: 5,681
Ïîáëàãîäàðèëè 1,128 ðàç(à) çà 1,080 ñîîáùåíèé
aberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
From the Lymphoma Disease Management Team.... Memorial Sloan-Kettering Cancer Center

Failure-free survival - ?
Ñîáñòâåííî ãîâîðÿ, ýòî âåäü äîëæíà áûòü "âûæèâàåìîñòü áåç ïðîãðåññèðîâàíèÿ"? Íî â ñòàòüå îäíîâðåìåííî óïîìèíàþòñÿ îáà òåðìèíà.
È ðàñøèôðîâêè, ÷òî ïîä ýòèì ïîíèìàåòñÿ, ïîêà íå óâèäåë (â ñàìîé ñòàòüå).

While the Italian study was criticized for design flaws and conduct of the Stanford V arm, particularly with regard to the radiotherapy (RT) component, some indicated that Stanford V might not be effective outside its site of design and expertise.

Ñòýíôîðä-5 ìîæåò áûòü íåýôôåêòèâíîé âíå ñòåí ó÷ðåæäåíèÿ, ãäå áûëà ðàçðàáîòàíà è îïðîáîâàíà? :-)
Îòâåòèòü ñ öèòèðîâàíèåì
  #223  
Ñòàðûé 21.03.2010, 02:33
aberzoy aberzoy âíå ôîðóìà ÂÐÀ×
Âåòåðàí ôîðóìà
      
 
Ðåãèñòðàöèÿ: 03.02.2003
Ãîðîä: Îäåññà
Ñîîáùåíèé: 5,681
Ïîáëàãîäàðèëè 1,128 ðàç(à) çà 1,080 ñîîáùåíèé
aberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåaberzoy ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Òàê, Failure-free survival îïðåäåëèëè:
FFS was defined as time from start of treatment to last follow-up or disease progression, any post-treatment response less than CR, relapse, or death from any cause.
Îòâåòèòü ñ öèòèðîâàíèåì
  #224  
Ñòàðûé 23.03.2010, 14:28
Àâàòàð äëÿ qwerty
qwerty qwerty âíå ôîðóìà
ÑÏÅÖÈÀËÈÑÒ
      
 
Ðåãèñòðàöèÿ: 10.11.2004
Ãîðîä: Ñàíêò-Ïåòåðáóðã
Ñîîáùåíèé: 23,115
Ïîáëàãîäàðèëè 6,818 ðàç(à) çà 6,491 ñîîáùåíèé
Çàïèñåé â äíåâíèêå: 15
qwerty ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåqwerty ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåqwerty ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåqwerty ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåqwerty ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåqwerty ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåqwerty ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåqwerty ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåqwerty ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåqwerty ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåqwerty ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
À ëàòûíü åùå êòî-íèáóäü ïîìíèò?
Íóæíî ïåðåâåñòè âîò òàêîé òåêñò 19 âåêà:
"Taenia microsoma mihi.
T. capitis varii osculis magnis, rostello elongato subclavato, collo et articulis omnibus brevissimis, his obtusis, lemniscis marginalibus, unilateralibus.

Hab. Am. Hornschuch copiam speciminum a Scillingio in itest. Anatis mollissimae anno 1823. detectam et postmodum specimina iterum multa ibidem ab eodem d. 16 Januarii 1826. inventa benevole transmisit.

Descr. Longitudo a quarta pollicis parte usque ad semipollicem cicriter aequat. Latitudo exigua, ut vermiculi filis aemulentur. Color albus.
Caput subtilissimum, ut nudo oculo meo discernere in non valerem, subconicum, interdum etiam transverse ellipticum, osculi quatuor magnis, oblongis visis, lateralibus, et rostello quam caput longiore, tenuissimo, ad apicem crassum sensim aucto, inermi, instructum. Collum capite tenuis, eidem longitudine aequale, aut idem, sed vix bis superans. Articuli omnes tam subtiles, quos nec lente simplici, nec duplici usus distinguere potuerim, brevissimi, obtusi; primi collo latitudine aequales, sensim increscunt, ultimus more solito est rotundatus, obtusus. Lemnisci marginales, cylindrici aut interdum subclavati, unilaterales, ordino incerto positi, magnam partem articulorum, anterioribus exceptis, ornant, non in omnibus vero speciminibus adsunt."
Íàâåðíîå, ìîæíî è ÷åðåç Ïðîìïò ïðîãíàòü - ó íàñ åãî íåò è íå ðàçðåøàþò ñòàâèòü. Íî Ïðîìïò ñòàðûå òåêñòû ïåðåâîäèò î÷åíü ñòðàííî.
__________________
Åëåíà Åâãåíüåâíà Êîðíàêîâà, ïàðàçèòîëîã.
Îòâåòèòü ñ öèòèðîâàíèåì
  #225  
Ñòàðûé 25.03.2010, 00:17
Skirr Skirr âíå ôîðóìà
ÂÐÀ×
      
 
Ðåãèñòðàöèÿ: 20.11.2008
Ãîðîä: Ïèòåð
Ñîîáùåíèé: 1,789
Ñêàçàë(à) ñïàñèáî: 4
Ïîáëàãîäàðèëè 464 ðàç(à) çà 416 ñîîáùåíèé
Skirr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSkirr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSkirr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSkirr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSkirr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSkirr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSkirr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSkirr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSkirr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSkirr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìåSkirr ýòîò ó÷àñòíèê èìååò ïðåâîñõîäíóþ ðåïóòàöèþ íà ôîðóìå
Ñòèëèñòè÷åñêèå îøèáêè èñïðàâëÿéòå ñàìè.

Öèòàòà:
Taenia microsoma mihi (mihi – ñîáñòâåííî? Ñåáå?)
Ò. ðàçëè÷íûõ ãîëîâîê ïðèñîñêà áîëüøàÿ, õîáîòîê óäëèíåííûé áóëàâîâèäíûé, øåÿ è ñóñòàâû âñå óêîðî÷åíû, His (îíè æå?) ïðèòóïëåíû, lemniscis (ëåìíèñêè – áàíòèêè?) êðàåâûå, îäíîñòîðîííèå.
Hab. Am. Hornschuch (èñòî÷íèê?) çàïàññÿ îáðàçöîì, êîòîðûé îáíàðóæèë Øèëëèíã â êèøå÷íèêå ãàãè [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] â 1823 è â ïîñëåäóþùåì îáðàçöû ïîâòîðíî âî ìíîæåñòâå òàì æå è òàê æå è 16 ÿíâàðÿ 1826 íàéäåííîå ìèëîñòèâî ïåðåñëàë.
Îïèñàíèå. Äëèíà ÷àñòè ïðèáëèçèòåëüíî îò ÷åòâåðòè äþéìà äî ïîëóäþéìà. Øèðèíà íåáîëüøàÿ, äîñòèãàåò øåëêîâîé íèòè. Öâåò áåëûé.
Ãîëîâà ìåëü÷àéøàÿ, èíîãäà íå â ñîñòîÿíèè ðàñïîçíàòüñÿ ìîåìó íåâîîðóæ¸ííîìó ãëàçó, ñóáêîíè÷åñêàÿ (íåñêîëüêî êîíè÷åñêàÿ?), èíîãäà åù¸ íàèñêîñü ÿéöåîáðàçíàÿ, ïðèñîñîê ÷åòûðå áîëüøèå, ïðîäîëãîâàòîãî âèäà, ëàòåðàëüíûå, è õîáîòîê äëèííåå ãîëîâêè, òîí÷àéøèé, íàä âåðõóøêîé ïîñòåïåííî óòîëùàåòñÿ, áåçîðóæíûé (?), âûñòàâëåí (íàñòàâëåí? Óïîðÿäî÷åí?). Øåÿ ãîëîâû òîíêàÿ, òàêîé æå îäèíàêîâîé äëèíû, èëè òàêæå îò íåáîëüøîãî äî äâîéíîãî ïðåâîñõîäñòâà. Ñóñòàâû (÷àñòè?) êàæäûé íàñòîëüêî ìåëêèå, ÷òî è íå ïðîñòûå, è íå äâîéíûå, ðàçëè÷èòü íå â ñîñòîÿíèè, î÷åíü êîðîòêèå, òóïûå; ïåðâûå ïî äëèíå ðàâíû øåå, ïîñòåïåííî âûðàñòàþò, ïîñëåäíèé îáûêíîâåííî êðóãëûé, òóïîé. Ëåìíèñêè (áàíòèêè? ) êðàåâûå, öèëèíäðè÷åñêèå èëè èíîãäà áóëàâîâèäíûå, îäíîñòîðîííèå, óñòðîåíû íåîïðåäåë¸ííûì ïîëîæåíèåì, áîëüøåé ÷àñòüþ ñëó÷àéíî (÷àñòè÷íî?), èñêëþ÷èòåëüíî êïåðåäè, óêðàøåíû (ñíàáæåíû?), íî íå âñå îäíàêî èäåàëüíî ïðèñóòñòâóþò.
Ïîõîæå, ÷òî [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] ïðî òî æå ñàìîå íà àíãëèéñêîì...

Öèòàòà:
Taenia microsonia was discovered by Schilling in Greenland in 1823, who found it-abundantly parasitic in the intestine of Anas moUissima. He-submitted his specimens to Creplin, who, in Novae observationes de Entozois Berolina, 1829, reported on them under the name Taenia microsoma. Krabbe merely says that the genital pores were unilateral and that the small head was hookless. Dujardin, Hist, des Helminths, p. 610, No. 132, supplies us with a little more information respecting Schilling's worm, and says that " Creplin's specimens were very young, only 7-13 mm. in length, as thin or thinner than a piece of fine thread ; the cirrus was cylindrical, almost claviform. The form of the head was variable; suckers large; proboscis or rostellum elongate-claviform ; the neck and all the segments were very short."
Îòâåòèòü ñ öèòèðîâàíèåì
Îòâåò



Âàøè ïðàâà â ðàçäåëå
Âû íå ìîæåòå ñîçäàâàòü òåìû
Âû íå ìîæåòå îòâå÷àòü íà ñîîáùåíèÿ
Âû íå ìîæåòå ïðèêðåïëÿòü ôàéëû
Âû íå ìîæåòå ðåäàêòèðîâàòü ñîîáùåíèÿ

BB êîäû Âêë.
Ñìàéëû Âêë.
[IMG] êîä Âêë.
HTML êîä Âûêë.



×àñîâîé ïîÿñ GMT +3, âðåìÿ: 15:38.




Ðàáîòàåò íà vBulletin® âåðñèÿ 3.
Copyright ©2000 - 2024, Jelsoft Enterprises Ltd.